Medisolv Expands AI Capabilities to Enhance Value-Based Care through Lilac Software Acquisition

Medisolv Strengthens AI Prowess with Recruitment of Lilac Software

In a significant move to enhance its strategic capabilities, Medisolv, Inc. has announced the acquisition of Lilac Software, Inc. This merger aims to bolster the company's efforts in value-based care through the integration of advanced AI-driven predictive analytics within its service framework.

Medisolv, recognized nationally for excellence in healthcare quality data management, has been at the forefront of aiding hospitals and accountable care organizations (ACOs) for over 25 years. With more than 1,800 hospitals benefiting from its expertise, Medisolv manages nearly a quarter of the healthcare facilities across the United States, impacting over 150 million patient records.

The acquisition of Lilac Software marks a significant evolution in Medisolv's journey, as it now aims to provide predictive, AI-powered quality intelligence to navigate the increasingly intricate landscape of value-based care. This integration is designed to not only enhance clinical quality measurement but also provide new insights into claims-based quality measurement, which is crucial for HEDIS performance analytics and early risk identification.

David Lucey, Jr., the CEO of Medisolv, emphasized the importance of this acquisition, stating, "Our mission has always been to enable healthcare organizations to understand and improve their quality performance. With Lilac, we transition from mere measurement to prediction and actual impact in care delivery. Our goal is to create a platform that actively helps close gaps in healthcare delivery."

Conversely, Neetu Rajpal, Co-Founder and CEO of Lilac, expressed enthusiasm over merging their innovations with Medisolv’s legacy in clinical quality management. "By amalgamating our AI capabilities with Medisolv's in-depth clinical expertise, we aim to accelerate the development of a new generation of solutions that not only quantify performance but also actively enhance it."

The integration of Lilac's patient outreach technology into Medisolv's existing support structure is set to transform how healthcare organizations engage with patients. This will facilitate the collection of critical quality data while addressing patient-reported outcome performance measures and enhancing workflows for information transfer.

Moreover, the combined technologies are poised to significantly improve healthcare organizations' abilities to identify care gaps through scalable patient outreach and predictive analytics, which will ultimately lead to more effective healthcare delivery at reduced administrative costs. By uniting clinical data from providers with claims-based insights from payers, the acquisition offers a holistic view of quality performance, making reporting less burdensome and more effective.

As Medisolv continues to steer the healthcare industry towards enhanced quality and performance, this acquisition will undoubtedly pave the way for progressive changes in patient care dynamics across the U.S. healthcare landscape. In sum, Medisolv's continuous efforts to integrate advanced technologies like AI into healthcare underscore its commitment to improving care quality while adapting to evolving industry demands. This acquisition stands as a testament to its forward-thinking approach within the demanding realm of healthcare.

For more information about Medisolv and its services, visit Medisolv website.